ARPI

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Prostate CancerProstatic Neoplasm

Phase 2

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Active, not recruitingNCT05849298

Novartis PharmaceuticalsProstatic Neoplasm

Start: 2024-01-03End: 2026-12-23Updated: 2026-03-03

Phase 3

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

RecruitingNCT06855277

Novartis PharmaceuticalsProstate Cancer

Start: 2025-07-01End: 2032-11-04Target: 940Updated: 2026-02-24

Related Papers

Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients: a tumor marker prognostic study

International Journal of Surgery2025-03-263 citations